KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosure Of Related Party Transactions For The Half Year Ended 30Th September, 2022, Pursuant To Regulation 23(9) Of Tile SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In accordance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the disclosure of Related Party Transactions of the Company for the half-year ended 30th September, 2022. KILITCH DRUGS (INDIA) LTD. - 524500 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication pertaining to the extract of the financial results of the Company for the quarter ended 30th September, 2022. The said extract of the financial results was published on Marathi and English edition on 15th November, 2022. KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Outcome for Approval Of Financial Results For The Period Ended 30Th September, 2022
In continuation of our letter dated 3rd November, 2022 and pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, 14th November, 2022 have considered and approved the following; 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th September, 2022. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith for your ready reference. KILITCH DRUGS (INDIA) LTD. - 524500 - Financial Results For The Quarter Ended 30Th September, 2022
In continuation of our letter dated 3rd November, 2022 and pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, 14th November, 2022 have considered and approved the following; 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th September, 2022. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith for your ready reference. KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for Intimation Of The Board Meeting To Consider The Financial Results For The Quarter Ended 30Th September, 2022
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Meeting of the Board of Directors of the Company will be held on Monday, 14th November, 2022 inter-alia to consider and approve the Standalone and Consolidated un-audited Financial Results of the Company for the quarter ended 30th September, 2022. KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018, enclosed herewith is the Certificate received from Link Intime India Private Limited, the Registrar and Share Transfer Agent of the Company for the quarter ended 30th September, 2022. KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosure Of Receipt Of Another Tranche Of Consideration Of Warrants Convertible Into Equity Shares
Disclosure of receipt of another tranche of consideration of warrants convertible into equity shares from allottees of the company KILITCH DRUGS (INDIA) LTD. - 524500 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
As per the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Company had provided remote e-voting and e-voting facility (during AGM) to its members on the business transacted at the 30th Annual General Meeting (AGM) of the Company held on Thursday, 29th September, 2022 at 10:00 A.M. through Video Conferencing (VC)/Other Audio Video Means (OAVM). The Company had appointed M/s. Deep Shukla & Associates, Practicing Company Secretary as the scrutinizer for the remote e-voting and e-voting facility at the AGM. As per the Scrutinizer's Report, all resolutions as set out in the Notice of 30th Annual General Meeting have been duly approved by the members of the Company. Please find attached voting results and the Scrutinizer's Report on voting held through e-voting at the 30th AGM of the Company. KILITCH DRUGS (INDIA) LTD. - 524500 - Closure of Trading Window
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with Code of Prohibition of Insider Trading of the Company, the Trading Windows for dealing in Securities of the Company will remain closed for all the Designated Persons of the Company and their immediate relatives with effect from Saturday, 1st October, 2022 till the expiry of 48 hours after the declaration of Financial Results of the Company for the quarter ended 30th September, 2022. The date of meeting of Board of Directors to approve the unaudited Financial Results of the Company for the quarter ended 30th September, 2022 will be intimated in due course. KILITCH DRUGS (INDIA) LTD. - 524500 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Dear Sir, Please find proceeding of 30th Annual General Meeting of the Companhy